Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC

January 19, 2016
Renato G. Martins, MD, MPH

Special Reports, NSCLC (Issue 10), Volume 10, Issue 10

​Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non

Renato G. Martins, MD, MPH, Medical Director, Thoracic/Head and Neck Medical Oncology, Seattle Cancer Care Alliance, discusses nivolumab in non—small cell lung cancer (NSCLC). Martins says while there are a number of trials where nivolumab is being combined with chemotherapy to increase its efficacy, the treatment is not ready for the firstline. He says until there is a reliable biomarker to identify which patients would benefit from the treatment, it would be difficult to move nivolumab into the frontline.